ClinicalTrials.gg

Multiple Sclerosis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,271 studies for Multiple Sclerosis across more than 10 countries. 665 are recruiting or about to start. 2,612 of them are mainly about Multiple Sclerosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Multiple Sclerosis, Relapsing-Remitting: 3,674 studies, 711 open.

ClinicalTrials.gov finds 3,965 studies for Multiple Sclerosis. How that becomes 3,269 here

This page counts the studies the registry files under Multiple Sclerosis, and those it files under no condition that list Multiple Sclerosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 3,965Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −403Filed under a narrower condition, counted on its own pageMultiple Sclerosis, Relapsing-Remitting 311 · Multiple Sclerosis, Chronic Progressive 90
  3. −17List Multiple Sclerosis as a condition, but the registry did not file them under itMost often written as “Relapsing Multiple Sclerosis” (5), “Multiple Sclerosis Transplant” (1), and “Multiple Sclerosis Stem Cell Transplant” (1). The registry filed them under other conditions only, most often Recurrence (3) and Motor Activity (3).
  4. −276Match it another way47 name it in the title, 1 in a keyword, and 228 by a synonym or other text the search reads.
  5. 3,269The count on this page104 of them list Multiple Sclerosis in their own words; the registry filed them under no condition.

Status

Completed
1,817
Recruiting
433
Status unknown
324
Terminated
200
Not yet recruiting
180
Active, not recruiting
168

Phase

Phase 2
403
Phase 3
274
Phase 1
256
Phase 4
180
Early Phase 1
30

Where

United States
1,192
France
376
Turkey
308
Italy
289
Canada
257
Germany
252

Who develops what

Add Multiple Sclerosis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 39 programs from 32 companies, 25 with this as their studies’ main aim; 11 with a live phase 3 study; 10 primary completions in the next 12 months. Compare Hoffmann-La Roche, Biocad and Biogen here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ocrelizumabRecent, repeated
Evidence
  • NCT07321093 · Biocad · Phase 3 · live · comparator · “Ocrelizumab” · registered Nov 2025
  • NCT06846281 · Novartis · Phase 3 · live · comparator · “Ocrelizumab” · registered Feb 2025
  • NCT06847724 · Sandoz · Phase 3 · live · comparator · “Ocrevus-EU” · registered Feb 2025
  • NCT04966338 · cinnagen · Phase 3 · comparator · “Ocrelizumab (Roche, Switzerland)” · registered Jun 2021
Hoffmann-La Roche90% of its industry studiesUS: Hoffmann-La Roche (FDA 2017)EU: Hoffmann-La Roche (EMA 2018)33 studies
Dimethyl FumarateRecent, repeated
Evidence
  • NCT07776743 · Lupeng Pharmaceutical Ltd. · Phase 2 · live · comparator · “Dimethyl Fumarate” · registered Aug 2026
  • NCT05417269 · Imcyse SA · Phase 2 · live · comparator · “Dimethyl Fumarate” · registered Jun 2022
Biogen89% of its industry studiesUS: off-patent, 10 generics marketedEU: off-patent, 3 generics authorized22 studies

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ublituximabApproved: US 2022 · EU 2023☆ Track4 live phase-3 studies: NCT04130997, NCT07220252, NCT05877963TG Therapeutics, Inc.
frexalimab☆ Track4 live phase-3 studies: NCT07930624, NCT06141486, NCT07325292Sanofi
ocrelizumabApproved: US 2017 · EU 2018☆ Track4 live phase-3 studies: NCT04544436, NCT05269004, NCT06675955Hoffmann-La Roche
remibrutinibApproved: US 2025 · EU 2026☆ Track2 live phase-3 studies: NCT06846281, NCT07225504Novartis
fenebrutinib☆ Track3 live phase-3 studies: NCT07937852, NCT04586010, NCT04586023Hoffmann-La Roche

The 5 in phase 3 with the nearest primary completion, of 39 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (10)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.Autologous HB-adMSCs · Hope Biosciences Research Foundation · Phase 2 named, not the main aimNCT06800404 "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" — primary endpoint: Change from Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument scores · 10 enrolled
  • 21 Jan 2027 est.ublituximab · TG Therapeutics, Inc. · Phase 3 main aimNCT05877963 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — primary endpoint: Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 · 800 enrolled
  • Apr 2027 est.luvesilocin · Reunion Neuroscience Inc · Phase 2 registry mapping onlyNCT07002034 RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses — primary endpoint: RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score · 100 enrolled

7 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Multiple Sclerosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open · Antihistamines 4 open · Antimetabolites 3 open · Serotonin receptor agonists 2 open · Potassium channel blockers 1 open

Coming up

223studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger. 40 (9%) take children under 18. 20 (5%) are for women only and 1 (<1%) for men only; 96 (22%) take healthy volunteers.

Recruiting studies that take each age, of 433
AgeWomenMen
1032 (7%)29 (7%)
18386 (89%)372 (86%)
30410 (95%)391 (90%)
40413 (95%)395 (91%)
50408 (94%)390 (90%)
65354 (82%)344 (79%)
75247 (57%)239 (55%)
85200 (46%)192 (44%)

Across all 3,271 studies, recruiting or not: 59% stop at 75 or younger and 48% at 65; 8% take children; 3% are for women only and 1% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Multiple Sclerosis studies take

Of 96 phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 130 mo9–56 · 92 studies13 mo6–32 · 39 studies50 mo19–71 · 53 studies
Phase 1/247 mo31–89 · 33 studies——
Phase 236 mo19–64 · 92 studies25 mo16–47 · 43 studies42 mo31–68 · 49 studies
Phase 342 mo26–63 · 96 studies39 mo25–54 · 71 studies—
Phase 434 mo23–59 · 69 studies29 mo19–37 · 36 studies—
Interventional, no phase21 mo9–43 · 872 studies—22 mo9–43 · 850 studies
Observational41 mo15–75 · 426 studies49 mo27–75 · 91 studies36 mo13–81 · 335 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered24

Show 19 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,271. Browse all 3,271 → or search them.